Business Wire

Synergis Software to Host Drawing Management & Collaboration Panel with Leaders from Eversource, Hoosier, and Great River Energy

30.3.2022 15:21:00 EEST | Business Wire | Press release

Share

Synergis Software, a global leader in engineering document management and workflow solutions, is hosting a free live panel for engineering, operations, and IT leaders who want to learn how to overcome drawing management and collaboration chaos and create a more resilient, adaptable, and secure utility.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220330005277/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Synergis Software to Host Drawing Management and Collaboration Panel with Leaders from Eversource, Hoosier, and Great River Energy. Engineering and IT experts from three Utilities come together for a live webinar to discuss the costs of drawing management chaos, their solutions, the business impact, and best practices. (Graphic: Business Wire)

The live 90-minute webinar will take place on Wednesday, April 6, 2022, at 2:00 p.m. EDT. The panel will be moderated by Scott Lamond, Vice President at Synergis Software with these guest panelists:

  • Paul J. Melzen, P.E., Director, Eversource Substation Engineering & Design
  • Blake Donley, Principal Systems Analyst, Great River Energy
  • Bernie Voges, Senior Protection Engineer, Hoosier Energy

Discussion topics will include the advantages of a centralized platform for drawing management and collaboration, best practices, and lessons learned for implementation and user adoption. Attendees will gain insights that will help them:

  • Align engineering, construction, field service, and operations
  • Ensure fast access to the right version, day or night
  • Eliminate expensive mistakes and outages
  • Simplify collaboration and accelerate projects
  • Capture tribal knowledge and secure digital assets
  • Streamline compliance and drive standards

The live Q&A session will allow attendees to get their questions answered.

Register now to reserve your seat, and if you can't attend, register to receive a replay.

“Our utility customers know the hidden costs and inefficiencies of doing business without a centralized drawing management and collaboration solution that aligns engineering, field service, operations, and construction,” says Scott Lamond, vice president at Synergis Software. “With our Adept engineering document management solution, utilities will increase asset reliability, improve operational efficiency, reduce compliance and safety risk, and lower operating costs.”

Paul Melzen, director, Eversource substation engineering and design says, “In addition to configuration control, drawing management has become more and more critical to reliability and compliance. If the drawings don't represent what's in the field, it's just a human error trap."

“When the people in the field can’t find the correct drawing, it can result in more man-hours spent to resolve an issue, which can have a direct impact on our customers,” adds Melzen. “Moreover, if we're designing and bidding on a project using inaccurate drawings, we’re exposing ourselves to the risk of change orders from our engineering and construction contractors. Not only can these issues have significant cost impacts to the company, but they can also impact compliance, reliability and safety.”

Synergis Adept is a proven solution used by utility customers such as Con Edison, Northwestern Energy, San Diego Gas & Electric, Dominion Energy, Emera Companies, Lansing Board of Water and Light, California Water Authority, Platte River Authority, Turlock Irrigation District and more.

For further information on the webinar or to register, visit the event page event page. If you can't attend, register to receive the replay.

About Synergis Software

Synergis Software is a global leader in document management and workflow solutions and is the creator of Synergis Adept software. Adept serves more than 120,000 users across dozens of industries providing fast, centralized access to design and business documents in a secure, collaborative environment. Adept Integrator connects your enterprise applications so your data and business processes flow seamlessly across your entire IT infrastructure.

Named the customer service leader in the global engineering information management market by Frost & Sullivan and ranked in the Top 5 globally by Helpdesk International for three consecutive years, our commitment to clients is unwavering.

Founded in 1985, Synergis Technologies, LLC is headquartered in Bucks County, PA and is privately owned and funded.

About Eversource

Eversource (NYSE: ES), celebrated as a national leader for its corporate citizenship, is the #1 energy company in Newsweek’s list of America’s Most Responsible Companies for 2021 and recognized as one of America’s Most JUST Companies. The #1 energy efficiency provider in the nation, the company is empowering a clean energy future in the Northeast, with nationally recognized energy efficiency solutions and successful programs to integrate new clean energy resources like solar, offshore wind, electric vehicles, and battery storage, into the electric system.

About Great River Energy

Great River Energy (GRE) is wholesale power cooperative; our member-owners are 28 Minnesota electric distribution cooperatives. Individuals and businesses are members of those distribution cooperatives based on their geographic location.

As a Touchstone Energy Cooperative, GRE is a part of a nationwide alliance made of more than 750 electric cooperatives in 46 states.

About Hoosier Energy

Hoosier Energy serves 18-member electric cooperatives in central and southern Indiana and southeastern Illinois. Founded in 1949 and based in Bloomington, Indiana, Hoosier Energy is a generation and transmission electric cooperative providing wholesale power and services to member distribution cooperatives. Their portfolio includes coal, natural gas and renewable energy resources that deliver power through a nearly 1,700-mile transmission network.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Scott Lamond
Vice President of Marketing
Email: scott.lamond@synergis.com
Phone: 215-302-3006

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye